You are here

  • Home
  • Archive
  • Volume 9, Issue 8
  • Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis

 

Online download statistics by month:

Online download statistics by month: August 2021 to March 2026

AbstractFullPdf
Aug 2021581580131
Sep 2021608609172
Oct 2021360360119
Nov 202126526668
Dec 202122522574
Jan 202220220782
Feb 202218619469
Mar 202224825384
Apr 202227628285
May 2022394403110
Jun 2022274278103
Jul 202229830670
Aug 202229629996
Sep 202224324685
Oct 202223124273
Nov 202223323580
Dec 202214714790
Jan 202318318372
Feb 202326726886
Mar 2023194195119
Apr 202316116180
May 202315716362
Jun 202315815967
Jul 202314114166
Aug 202316316480
Sep 202320921589
Oct 202318518566
Nov 202318118184
Dec 202319920075
Jan 2024129130110
Feb 202417517566
Mar 202417517589
Apr 202415415678
May 202411511546
Jun 2024919060
Jul 202410610742
Aug 2024848148
Sep 2024959565
Oct 202411611653
Nov 20249810247
Dec 20249710140
Jan 202514214349
Feb 2025909061
Mar 2025636345
Apr 202514814895
May 202510310395
Jun 2025666745
Jul 2025110
Sep 2025210
Mar 2026110
Total931694073671